Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Destiny Pharma to Join Equity Development Webinar on Positive Phase 2b Top-line Results for XF-73 Nasal Gel
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Stocks that may or may not make the grade in the papers
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that the outline
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), is pleased to announce the admission